Cell and Gene Therapies (CGTs) represent one of the most transformative innovations in modern medicine, offering curative potential for previously untreatable diseases. Today, the CGT market is valued at $15.48 billion, and with breakthrough approvals, increased investment and a rapidly expanding pipeline, it is projected to grow to $28.9 billion by 2029 [1].